Mobile

An Open-Label, Multi-Centre, Randomised Parallel Group Comparison of Efficacy and Safety of Degarelix Three-Month Depot in Three Different Dosing Regimens of 240 mg (40 mg/mL) and 240 mg (60 mg/mL) in...

Update Il y a 5 ans
Reference: EUCTR2004-003815-22

An Open-Label, Multi-Centre, Randomised Parallel Group Comparison of Efficacy and Safety of Degarelix Three-Month Depot in Three Different Dosing Regimens of 240 mg (40 mg/mL) and 240 mg (60 mg/mL) in Patients with Prostate Cancer Requiring Androgen Ablation Therapy

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

•To demonstrate that the efficacy in achieving and maintaining testosterone castration levels (<=0.5 ng/mL) in prostate cancer patients treated up to either 12 or 13 months is at least 80%.

Inclusion criteria

  • Prostate cancer

Links